AR069526A1 - Compuesto heterociclico que contiene nitrogeno y su uso - Google Patents
Compuesto heterociclico que contiene nitrogeno y su usoInfo
- Publication number
- AR069526A1 AR069526A1 ARP080105249A ARP080105249A AR069526A1 AR 069526 A1 AR069526 A1 AR 069526A1 AR P080105249 A ARP080105249 A AR P080105249A AR P080105249 A ARP080105249 A AR P080105249A AR 069526 A1 AR069526 A1 AR 069526A1
- Authority
- AR
- Argentina
- Prior art keywords
- methoxy
- methoxypropoxy
- rac
- benzamide
- substituent
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 title 2
- 229910052757 nitrogen Inorganic materials 0.000 title 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 abstract 6
- 125000001424 substituent group Chemical group 0.000 abstract 6
- -1 3-methoxypropoxy Chemical group 0.000 abstract 5
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 abstract 5
- 235000010290 biphenyl Nutrition 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- 102000007124 Tachykinin Receptors Human genes 0.000 abstract 1
- 108010072901 Tachykinin Receptors Proteins 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 210000001635 urinary tract Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Dado que el compuesto accion antagonista del receptor de taquiquinina superior, y es util como un agente para la profilaxis o el tratamiento de varias enfermedades tales como enfermedades del tracto urinario inferior, enfermedades gastrointestinales, enfermedades del sistema nervioso central y similares. Reivindicacion 1: Un compuesto caracterizado por la formula (1) en la cual el anillo A es un heterociclo que contiene nitrogeno que en forma opcional tiene además sustituyente(s), el anillo B es un anillo aromático que tiene en forma opcional sustituyente(s), el anillo C es un grupo cíclico que tiene en forma opcional sustituyente(s), R1 es un átomo de hidrogeno, un grupo hidrocarbonado que tiene en forma opcional sustituyente(s), un grupo acilo, un grupo heterocíclico que tiene en forma opcional sustituyente(s) o un grupo amino que tiene en forma opcional sustituyente(s), R2 es un grupo alquilo C1-6 opcionalmente halogenado, m y n son cada uno un numero entero de 0 hasta 5, m+n es un numero entero de 2 hasta 5, y ------- es un enlace simple o un enlace doble (excepto N-[(rac.)-(3R,4R)-1-bencil-4-fenilpiperidin-3-il]-N-isopropil-4-metoxi-3-(3-metoxipropoxi)benzamida, N-isopropil-4-metoxi-3-(3-metoxipropoxi)-N-(rac.)-(3R,4R)-4-fenilpiperidin-3-il]benzamida, N-isopropil-4-metoxi-3-(3-metoxipropoxi)-N-[(rac.)-(3R,4R)-4-(3-(metilsulfonil)amino-fenil)-piperidin-3-il]benzamida, N-isopropil-[(rac.)-(3R,4R)-4-[1,1'-bifenil]-3-i-3- piperidinil]-4-metoxi-3-(3-metoxipropoxi)benzamida, N-etil-[(rac.)-(3R,4R)-4-[1,1'-bifenil]-3-il-3-piperidinil]-4-metoxi-3-(3-metoxipropoxi)benzamida, N-propil-[(rac.)-(3R,4R)-4-[1,1'-bifenil]-3-il-3-piperidinil]-4-metoxi-3-(3-metoxipropoxi)benzamida, N-etil-[(rac.)-(3R,4R)-4-[3-[(3,5-dimetoxifenil)metoxi]fenil]-3-piperidinil]-4-metoxi-3-(3-metoxipropoxi)benzamida y 4-metoxi-3-(3-metoxipropoxi)-N-isopropil-N-[(rac.)-4-(4-fenil-2-oxazolil)-3-piperidinil)benzamida), o una de sus sales.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99673407P | 2007-12-03 | 2007-12-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR069526A1 true AR069526A1 (es) | 2010-01-27 |
Family
ID=40340719
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080105249A AR069526A1 (es) | 2007-12-03 | 2008-12-02 | Compuesto heterociclico que contiene nitrogeno y su uso |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8470816B2 (es) |
| AR (1) | AR069526A1 (es) |
| CL (1) | CL2008003595A1 (es) |
| PE (1) | PE20091093A1 (es) |
| TW (1) | TW200930713A (es) |
| WO (1) | WO2009072643A1 (es) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2002835A1 (en) | 2007-06-04 | 2008-12-17 | GenKyo Tex | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
| CN102066321A (zh) * | 2008-06-16 | 2011-05-18 | 弗·哈夫曼-拉罗切有限公司 | 作为nk2受体拮抗剂的吡咯烷衍生物 |
| EP2336105B9 (en) | 2008-09-19 | 2014-09-17 | Takeda Pharmaceutical Company Limited | Nitrogen-containing heterocyclic compound and use of same |
| EP2165707A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
| EP2166009A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as nadph oxidase inhibitors |
| EP2166010A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
| US8022099B2 (en) * | 2008-11-03 | 2011-09-20 | Hoffmann-La Roche Inc. | N-benzyl pyrrolidine derivatives |
| EP2305679A1 (en) | 2009-09-28 | 2011-04-06 | GenKyoTex SA | Pyrazoline dione derivatives as nadph oxidase inhibitors |
| EP2361912A1 (en) * | 2010-02-18 | 2011-08-31 | GenKyoTex SA | Pyrazolo piperidine derivatives as NADPH oxidase inhibitors |
| PL2552920T3 (pl) | 2010-04-02 | 2017-08-31 | Ogeda Sa | Nowe wybiórcze związki antagonistów receptora NK-3, farmaceutyczne kompozycje i sposoby do zastosowania w zaburzeniach pośredniczonych przez receptory NK-3 |
| US10065960B2 (en) | 2010-04-02 | 2018-09-04 | Ogeda Sa | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders |
| US9428547B2 (en) | 2010-04-21 | 2016-08-30 | Dna Electronics, Inc. | Compositions for isolating a target analyte from a heterogeneous sample |
| US8841104B2 (en) | 2010-04-21 | 2014-09-23 | Nanomr, Inc. | Methods for isolating a target analyte from a heterogeneous sample |
| US20110262989A1 (en) | 2010-04-21 | 2011-10-27 | Nanomr, Inc. | Isolating a target analyte from a body fluid |
| US9476812B2 (en) | 2010-04-21 | 2016-10-25 | Dna Electronics, Inc. | Methods for isolating a target analyte from a heterogeneous sample |
| CA2849751C (en) | 2011-10-03 | 2019-06-11 | Euroscreen Sa | Chiral n-acyl-5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, methods for use in nk-3 receptormediated disorders and chiral synthesis thereof |
| US10000557B2 (en) | 2012-12-19 | 2018-06-19 | Dnae Group Holdings Limited | Methods for raising antibodies |
| US9551704B2 (en) | 2012-12-19 | 2017-01-24 | Dna Electronics, Inc. | Target detection |
| US9434940B2 (en) | 2012-12-19 | 2016-09-06 | Dna Electronics, Inc. | Methods for universal target capture |
| US9995742B2 (en) | 2012-12-19 | 2018-06-12 | Dnae Group Holdings Limited | Sample entry |
| US9599610B2 (en) | 2012-12-19 | 2017-03-21 | Dnae Group Holdings Limited | Target capture system |
| US9804069B2 (en) | 2012-12-19 | 2017-10-31 | Dnae Group Holdings Limited | Methods for degrading nucleic acid |
| US9359330B2 (en) * | 2013-08-26 | 2016-06-07 | Purdue Pharma L.P. | Substituted piperidines as sodium channel blockers |
| WO2015161011A1 (en) * | 2014-04-17 | 2015-10-22 | Merck Sharp & Dohme Corp. | Benzamide cgrp receptor antagonists |
| EP3183248B1 (en) * | 2014-08-21 | 2020-11-11 | Bristol-Myers Squibb Company | Tied-back benzamide derivatives as potent rock inhibitors |
| CA2960280A1 (en) * | 2014-09-10 | 2016-03-17 | Epizyme, Inc. | Substituted piperidine compounds |
| EP3287441B1 (en) | 2015-04-20 | 2021-06-09 | Takeda Pharmaceutical Company Limited | Acylated 4-aminopiperidines as inhibitors of serine palmitoyltransferase |
| EP3405183A4 (en) * | 2016-01-18 | 2019-12-11 | Arisan Therapeutics Inc. | ADAMATE DERIVATIVES FOR TREATING A FILOVIRUS INFECTION |
| WO2018074461A1 (ja) | 2016-10-18 | 2018-04-26 | 武田薬品工業株式会社 | 複素環化合物 |
| EP3582783B1 (en) | 2017-02-17 | 2023-06-07 | Trevena, Inc. | 7-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same |
| KR20190129867A (ko) | 2017-02-17 | 2019-11-20 | 트레베나, 인코포레이티드. | 5-원 아자-헤테로고리 함유 델타-오피오이드 수용체 조절 화합물, 및 그의 사용 및 제조 방법 |
| WO2019018185A1 (en) | 2017-07-15 | 2019-01-24 | Arisan Therapeutics Inc. | ENANTIOMERICALLY PURE ADAMATANE DERIVATIVES FOR THE TREATMENT OF FILOVIRUS INFECTIONS |
| EP3479843A1 (en) | 2017-11-01 | 2019-05-08 | GenKyoTex Suisse SA | Use of nox inhibitors for treatment of cancer |
| MX2021006542A (es) | 2018-12-06 | 2021-07-07 | Almac Discovery Ltd | Inhibidores de la usp19 para usarse en terapia. |
| CN110357882B (zh) * | 2019-07-17 | 2020-10-16 | 深圳市华星光电半导体显示技术有限公司 | 含氮杂环的有机化合物及有机电致发光器件 |
| CN111961020A (zh) * | 2020-08-31 | 2020-11-20 | 南通大学 | 一种四氢吡喃羧酸衍生物及其合成方法 |
| EP4011877A3 (en) * | 2020-12-11 | 2023-01-11 | Institut de Cardiologie de Montréal | Method of treating elevated plasma cholesterol |
| US12115154B2 (en) | 2020-12-16 | 2024-10-15 | Srx Cardio, Llc | Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) |
| GB202311227D0 (en) | 2023-07-21 | 2023-09-06 | Almac Discovery Ltd | Pharmaceutical compounds |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5288725A (en) | 1992-10-15 | 1994-02-22 | Merck & Co., Inc. | Pyrroloquinoline Bradykinin antagonist |
| IT1283171B1 (it) | 1996-03-01 | 1998-04-16 | Interdipartimentale Di Ricerca | Composti solubili antagonisti delle tachichinine loro preparazione e loro uso in composizioni farmaceutiche |
| US20040082589A1 (en) | 2000-11-13 | 2004-04-29 | Carlo Farina | Quinoline derivatives as nk-3 and nk-2 antagonists |
| GB0027701D0 (en) | 2000-11-13 | 2000-12-27 | Smithkline Beecham Spa | Novel compounds |
| DE60208178T2 (de) | 2001-04-11 | 2006-08-24 | Glaxosmithkline S.P.A. | Chinolin-4-carboxamidderivate als nk-3 und nk-2 rezeptor antagonisten |
| BR0311425A (pt) | 2002-05-31 | 2005-03-15 | Takeda Pharmaceutical | Composto, pró-droga, método para preparar o composto, álcool oticamente ativo, e amina oticamemte ativa, e para prevenir e/ou tratar anormalidades ou doenças, medicamento, e, uso do composto ou de uma pró-droga deste |
| AU2003902882A0 (en) * | 2003-06-10 | 2003-06-26 | Fujisawa Pharmaceutical Co., Ltd. | Piperidyl derivatives |
| CA2552965A1 (en) | 2004-01-14 | 2005-07-28 | Takeda Pharmaceutical Company Limited | Carboxamide derivative and use thereof |
| MXPA06012323A (es) | 2004-04-28 | 2007-01-17 | Takeda Pharmaceutical | Derivado de quinolina fusionada y uso del mismo. |
| BRPI0510951A (pt) | 2004-05-12 | 2007-11-20 | Pfizer Prod Inc | derivados de piperidina como antagonistas de nk1 e nk3 |
| SE0403005D0 (sv) | 2004-12-09 | 2004-12-09 | Astrazeneca Ab | New use |
| EP2119702A4 (en) | 2007-01-31 | 2010-12-08 | Dainippon Sumitomo Pharma Co | amide derivative |
| JP2010163361A (ja) * | 2007-04-27 | 2010-07-29 | Dainippon Sumitomo Pharma Co Ltd | キノリン誘導体 |
-
2008
- 2008-12-02 AR ARP080105249A patent/AR069526A1/es unknown
- 2008-12-02 WO PCT/JP2008/072224 patent/WO2009072643A1/en not_active Ceased
- 2008-12-02 PE PE2008002010A patent/PE20091093A1/es not_active Application Discontinuation
- 2008-12-02 US US12/314,015 patent/US8470816B2/en active Active
- 2008-12-02 CL CL2008003595A patent/CL2008003595A1/es unknown
- 2008-12-02 TW TW097146722A patent/TW200930713A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US8470816B2 (en) | 2013-06-25 |
| WO2009072643A1 (en) | 2009-06-11 |
| US20090156572A1 (en) | 2009-06-18 |
| TW200930713A (en) | 2009-07-16 |
| PE20091093A1 (es) | 2009-08-25 |
| CL2008003595A1 (es) | 2009-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR069526A1 (es) | Compuesto heterociclico que contiene nitrogeno y su uso | |
| PE20141120A1 (es) | Compuestos heterociclicos | |
| PE20120861A1 (es) | Compuestos y composiciones como inhibidores de cinasa de proteina | |
| NO20063599L (no) | Ytterligere heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister | |
| PE20061357A1 (es) | COMPUESTOS DERIVADOS DE AMINOSULFONILO COMO INHIBIDORES DE LA 11-ß-HSD-1 | |
| PE20090890A1 (es) | Compuestos derivados de 1-(2,3-dihidrobenzo[1,4]dioxin-2-ilmetil)azaciclos como antagonistas del suptipo adrenoreceptor alfa2c | |
| PE20060427A1 (es) | Derivados de pirazol como inhibidores de la union del glucagon y composiciones | |
| PE20091974A1 (es) | Derivados de indazoles sustituidos con fenil o piridinilo | |
| AR065810A1 (es) | Derivados de isoindolina 4'-o-sustituidos,composiciones farmaceuticas que los comprenden y usos de los mismos en el tratamiento del cancer y en otros trastornos donde es necesario el control de la angiogenesis o la inhibicion de citoquinas, incluyendo tnf-alfa. | |
| NZ594597A (en) | Substituted piperidines as ccr3 antagonists | |
| PE20110136A1 (es) | Compuestos organicos | |
| NZ588652A (en) | Carboxamide compounds for the treatment of metabolic disorders | |
| PE20090288A1 (es) | Derivados de quinoxalina como inhibidores de la pi3 quinasa | |
| PE20121050A1 (es) | Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog | |
| UY31125A1 (es) | Formas amorfas estabilizadas de mesilato de imatinib | |
| PE20140934A1 (es) | Derivados de pirazol | |
| PE20141307A1 (es) | Aril dihidropiridinona y piperidinona como inhibidores de monoacilglicerol aciltransferasa (mgat2) | |
| PE20150194A1 (es) | Novedosas n-piridinil amidas ciclicas sustituidas como inhibidores de quinasa | |
| PE20091433A1 (es) | Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y procedimientos para su preparacion 177 | |
| UY29389A1 (es) | Derivados sustituidos del ácido1-((4-((((3,3-dimetil-2-oxo-2,3-dihidro-1h-indol-1-il)carbonil)amino)metil)piperidin-1-il)metil)ciclobutanocarboxílico, sales farmaceuticamente aceptables, composiciones que los contienen y aplicaciones. | |
| UY29766A1 (es) | Formas cristalinas delta y épsilon de mesilato de imatinib | |
| AR077642A1 (es) | Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo | |
| PE20171347A1 (es) | Compuestos con actividad antagonista de los receptores muscarinicos y actividad agonista del receptor beta2 adrenergico | |
| NO20071314L (no) | Peptidiske vasopressinreseptoragonister | |
| PE20090595A1 (es) | Derivados de quinoliniloxipiperidina y pirrolidina como antagonistas del receptor h1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |